Logo image of XGN

EXAGEN INC (XGN) Stock Fundamental Analysis

NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD

6.74  +0.71 (+11.77%)

Fundamental Rating

2

Overall XGN gets a fundamental rating of 2 out of 10. We evaluated XGN against 561 industry peers in the Biotechnology industry. XGN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, XGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XGN had negative earnings in the past year.
In the past year XGN has reported a negative cash flow from operations.
In the past 5 years XGN always reported negative net income.
In the past 5 years XGN always reported negative operating cash flow.
XGN Yearly Net Income VS EBIT VS OCF VS FCFXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -38.48%, XGN is in line with its industry, outperforming 56.86% of the companies in the same industry.
XGN has a worse Return On Equity (-242.18%) than 71.48% of its industry peers.
Industry RankSector Rank
ROA -38.48%
ROE -242.18%
ROIC N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
XGN Yearly ROA, ROE, ROICXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

With a decent Gross Margin value of 59.30%, XGN is doing good in the industry, outperforming 77.72% of the companies in the same industry.
In the last couple of years the Gross Margin of XGN has grown nicely.
XGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
XGN Yearly Profit, Operating, Gross MarginsXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XGN has more shares outstanding
The number of shares outstanding for XGN has been increased compared to 5 years ago.
XGN has a worse debt/assets ratio than last year.
XGN Yearly Shares OutstandingXGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
XGN Yearly Total Debt VS Total AssetsXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.63, we must say that XGN is in the distress zone and has some risk of bankruptcy.
XGN has a worse Altman-Z score (-7.63) than 70.23% of its industry peers.
XGN has a Debt/Equity ratio of 2.87. This is a high value indicating a heavy dependency on external financing.
XGN's Debt to Equity ratio of 2.87 is on the low side compared to the rest of the industry. XGN is outperformed by 83.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF N/A
Altman-Z -7.63
ROIC/WACCN/A
WACC10.2%
XGN Yearly LT Debt VS Equity VS FCFXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.32 indicates that XGN has no problem at all paying its short term obligations.
With a Current ratio value of 2.32, XGN is not doing good in the industry: 72.55% of the companies in the same industry are doing better.
XGN has a Quick Ratio of 2.32. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.32, XGN is doing worse than 70.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 2.32
XGN Yearly Current Assets VS Current LiabilitesXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.94% over the past year.
Looking at the last year, XGN shows a small growth in Revenue. The Revenue has grown by 1.77% in the last year.
XGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.62% yearly.
EPS 1Y (TTM)22.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.26%
Revenue 1Y (TTM)1.77%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%7.51%

3.2 Future

The Earnings Per Share is expected to grow by 17.41% on average over the next years. This is quite good.
The Revenue is expected to grow by 13.60% on average over the next years. This is quite good.
EPS Next Y31.25%
EPS Next 2Y30.22%
EPS Next 3Y23.12%
EPS Next 5Y17.41%
Revenue Next Year18.01%
Revenue Next 2Y15.61%
Revenue Next 3Y14.65%
Revenue Next 5Y13.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XGN Yearly Revenue VS EstimatesXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
XGN Yearly EPS VS EstimatesXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XGN Price Earnings VS Forward Price EarningsXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XGN Per share dataXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

XGN's earnings are expected to grow with 23.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.22%
EPS Next 3Y23.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXAGEN INC

NASDAQ:XGN (5/23/2025, 2:42:47 PM)

6.74

+0.71 (+11.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners45.44%
Inst Owner Change1.19%
Ins Owners9.17%
Ins Owner Change8.02%
Market Cap120.65M
Analysts82
Price Target6.89 (2.23%)
Short Float %0.92%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)1.81%
Max EPS beat(2)23.84%
EPS beat(4)4
Avg EPS beat(4)21.03%
Min EPS beat(4)1.81%
Max EPS beat(4)54.08%
EPS beat(8)8
Avg EPS beat(8)30%
EPS beat(12)10
Avg EPS beat(12)21.49%
EPS beat(16)14
Avg EPS beat(16)18.74%
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-2.37%
Max Revenue beat(2)5.51%
Revenue beat(4)2
Avg Revenue beat(4)2%
Min Revenue beat(4)-8.71%
Max Revenue beat(4)13.56%
Revenue beat(8)6
Avg Revenue beat(8)11.43%
Revenue beat(12)9
Avg Revenue beat(12)14.9%
Revenue beat(16)12
Avg Revenue beat(16)12.39%
PT rev (1m)0%
PT rev (3m)-3.57%
EPS NQ rev (1m)-7.42%
EPS NQ rev (3m)19.12%
EPS NY rev (1m)-0.89%
EPS NY rev (3m)16.91%
Revenue NQ rev (1m)-1.08%
Revenue NQ rev (3m)-2.86%
Revenue NY rev (1m)1.7%
Revenue NY rev (3m)-0.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.13
P/FCF N/A
P/OCF N/A
P/B 18.84
P/tB 18.84
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS3.17
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.48%
ROE -242.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.3%
FCFM N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
F-Score3
Asset Turnover1.41
Health
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.77%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 2.32
Altman-Z -7.63
F-Score3
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)115%
Cap/Depr(5y)136.67%
Cap/Sales(3y)3.99%
Cap/Sales(5y)3.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.26%
EPS Next Y31.25%
EPS Next 2Y30.22%
EPS Next 3Y23.12%
EPS Next 5Y17.41%
Revenue 1Y (TTM)1.77%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%7.51%
Revenue Next Year18.01%
Revenue Next 2Y15.61%
Revenue Next 3Y14.65%
Revenue Next 5Y13.6%
EBIT growth 1Y22.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.28%
EBIT Next 3Y32.35%
EBIT Next 5Y23.21%
FCF growth 1Y58.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.25%
OCF growth 3YN/A
OCF growth 5YN/A